Characteristic | ETGBS (n = 18) | PTGBD (n = 10) | P |
---|---|---|---|
Age | 71 (52–88) | 77 (48–86) | 0.23 |
Sex (male/female) | 15/3 | 7/3 | 0.41 |
Laboratory data before drainage | |||
WBC (cells/mm3) | 14650 (4700–36,400) | 12,500 (7600–18,300) | 0.29 |
Total bilirubin (mg/dl) | 1.7 (0.54–23.44) | 0.87 (0.44–3.9) | 0.30 |
Plt (× 109) | 18.8 (12–30.9) | 29.3 (6.4–31.2) | 0.77 |
Cre (mg/dl) | 0.70 (0.33–1.33) | 0.87 (0.61–10.33) | 0.12 |
AST (U/l) | 41 (17–578) | 28 (18–208) | 0.48 |
ALT (U/) | 42 (12–490) | 35 (8–121) | 0.23 |
ALP (U/l) | 215 (159–2368) | 239 (133–675) | 0.27 |
Alb (g/dl) | 3.2 (2.7–5.1) | 3.3 (2.9–4.6) | 0.51 |
CRP(mg/dl) | 15.7 (0.05–30.4) | 16.9 (0.3–43.7) | 0.30 |
PT–INR | 1.11 (0.99–1.43) | 1.02 (0.89–1.78) | 0.72 |
DIC | |||
Yes | 0 (0%) | 2 (20%) | 0.119 |
No | 18 (100%) | 8 (80%) | |
Ascites | |||
Yes | 0 (0%) | 0 (0%) | N.A |
No | 18 (100%) | 10 (100%) | |
Anticoagulant therapy | |||
Yes | 4 (22%) | 3 (30%) | 0.674 |
No | 14 (78%) | 7 (70%) | |
Time to operation (day) | 72 (11–118) | 78 (32–202) | 0.08 |
ASA* | |||
1 | 5 (28%) | 3 (30%) | 0.97 |
2 | 8 (44%) | 4 (40%) | |
3 | 5 (28%) | 3 (30%) | |
Grade** | |||
I | 12 (67%) | 7 (70%) | 0.08 |
II | 6 (33%) | 1 (10%) | |
III | 0 (0%) | 2 (20%) |